长春瑞滨联合顺铂治疗三阴性乳腺癌的临床研究

目的探讨长春瑞滨联合顺铂治疗三阴性乳腺癌的临床疗效和安全性。方法对我院2006年3月至2009年1月收治的41例明确诊断为三阴性乳腺癌的患者采用长春瑞滨联合顺铂治疗,评价患者化疗后的疗效和不良反应。结果临床疗效CR 7.3%(3/41)、PR 36.6%(15/41)、SD 36.6%(15/41)、PD 19.5%(8/41)、RR 43.9%(18/41)。化疗后随访至2012年2月,5例失访,中位TTP为6.0个月,不同转移部位的患者有效率不同,淋巴结和骨转移有效率最高,分别为60.9%(14/23)和38.9%(7/18)。患者化疗后不良反应主要为骨髓抑制、胃肠道反应、静脉炎等,未见化疗相关的死亡病例。结论长春瑞滨联合顺铂治疗三阴性乳腺癌临床疗效较好,且患者可耐受,值得临床进一步探讨和研究。

Clinical research of vinorelbine combined with cisplatin in the treatment for triple negative breast cancer

Objective To investigate the clinical efficacy and safety of vinorelbine combined with cisplatin in the treatment for triple negative breast cancer.Methods 41 patients with triple negative breast cancer were treated with vinorelbine and cisplatin.The efficacy and adverse reactions of all patients after chemotherapy were evaluated.Results There were 3 cases of CR(7.3%),15 cases of PR(36.6%),15 cases of SD(36.6%),8 cases of PD(19.5%),18 cases of RR(43.9%).The patients were followed up till February 2012 with 5 cases lost.The median TTP was 6.0 months,different sites of metastases in patients received different effective rates,the effective rate of lymph nodes and bone metastases were 60.9%(14/23)and 38.9%(7/18).Adverse reactions in patients after chemotherapy included myelosuppression,gastrointestinal reactions,phlebitis,and no chemotherapy-related deaths.Conclusion Vinorelbine combined with cisplatin in the treatment for triple negative breast cancer has good clinical efficacy,and the patient can tolerate the adverse reactions,and it is worthy of further exploration and study.